NCT04078698 - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

May 30, 2025

Study Completion Date

August 15, 2025

Conditions

Autoimmune Diseases

Interventions

DEVICE

Immunoadsorber GLOBAFFIN®

Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease

Trial Locations (3)

Diakonissenkrankenhaus Flensburg, Flensburg

Städtisches Klinikum Braunschweig, Braunschweig

University of Ulm - Department of Neurology, Ulm